MetaCap

Actuate Therapeutics (ACTU) vs BeyondSpring (BYSI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BeyondSpring (BYSI) has outperformed Actuate Therapeutics (ACTU) over the past year, losing 82.8% versus a loss of 96.4%. BeyondSpring is the larger company by market cap ($13.7 million vs $13.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACTU-96.43%BYSI-82.77%
+29%-37%-103%
Nov 21, 20251 yearNov 20, 2026
ACTU-97.41%BYSI-82.35%
+78%-14%-106%
Aug 12, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACTU versus BYSI key metrics
MetricACTUBYSI
Share price$0.2253$0.33
Market cap$13.60M$13.66M
1-day change+5.38%-24.49%
YTD return-96.32%-79.75%
1-year return-96.43%-82.77%
5-year return—-97.70%
EPS (TTM)$-0.76$-0.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)$-22.23M$-1.01M
52-week high$7.90$2.44
52-week low$0.174$0.299
Distance from 52-week high-97.15%-86.48%
Analyst consensusnone—
Avg. price target upside+5084.20%—
Average volume807.24K261.79K
Shares outstanding60.38M41.41M
Employees1244
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BYSI has outperformed ACTU by 13.7 percentage points over the past year.

About Actuate Therapeutics

ACTU stock →

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

About BeyondSpring

BYSI stock →

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees

ACTU vs BYSI FAQ

Which is bigger, Actuate Therapeutics or BeyondSpring?

BeyondSpring (BYSI) is larger, with a market capitalization of $13.66M compared with $13.60M for Actuate Therapeutics (ACTU).

Which stock has performed better over the past year, ACTU or BYSI?

BYSI returned -82.77% over the past 12 months, compared with -96.43% for ACTU (price return, excluding dividends). Past performance does not predict future results.

Are Actuate Therapeutics and BeyondSpring in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons